| Ημερομηνία | barcode | code | περιεχομενο | τιμή παραγωγός | χονδρική | λιανική |
|---|---|---|---|---|---|---|
| 05/2018 | 2802984301191 | 298430119 | ESOLIB GR.CAP 20MG/CAP BTx28 (OPA/Al/PVC-Alu blisters) (OPA/Al/PVC-Alu blisters) | 3.85 | 04.04 | 5.57 |
| 05/2018 | 2802984302198 | 298430219 | ESOLIB GR.CAP 40MG/CAP BTx28 (OPA/Al/PVC-Alu blisters) (OPA/Al/PVC-Alu blisters) | 4.52 | 4.74 | 6.53 |
For the treatment of acid-reflux disorders (GERD), peptic ulcer disease, H. pylori eradication, and prevention of gastroinetestinal bleeds with NSAID use.
Omeprazole is a proton pump inhibitor that suppresses gastric acid secretion by specific inhibition of the H<sup>+</sup>/K<sup>+</sup>-ATPase in the gastric parietal cell. By acting specifically on the proton pump, omeprazole blocks the final step in acid production, thus reducing gastric acidity.
Symptoms of overdose include confusion, drowsiness, blurred vision, tachycardia, nausea, diaphoresis, flushing, headache, and dry mouth.
Absorption is rapid, absolute bioavailability (compared to intravenous administration) is about 30-40% at doses of 20-40 mg.
0.5-1 hour
Urinary excretion is a primary route of excretion of omeprazole metabolites.
* total body cl=500-600 mL/min [healthy] * 250 mL/min [Geriatric] * 70 mL/min [Hepatic Impairment] * 10 - 62 mL/min/1.73 m2 [Renal Impairment]